tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

TCRR

Is TCRR a Buy, Before Earnings?
Pre-EarningsIs TCRR a Buy, Before Earnings?
2y ago
TCRR
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
PremiumThe Fly
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
2y ago
GSK
ADAP
Alaunos Therapeutics appoints Hofmeister to board of directors
PremiumThe Fly
Alaunos Therapeutics appoints Hofmeister to board of directors
2y ago
TCRR
TCRT
TCR2 Therapeutics downgraded to Neutral from Buy at Mizuho
PremiumThe Fly
TCR2 Therapeutics downgraded to Neutral from Buy at Mizuho
2y ago
ADAP
TCRR
TCR2 Therapeutics reports Q4 EPS ($1.56), consensus (79c)
PremiumThe Fly
TCR2 Therapeutics reports Q4 EPS ($1.56), consensus (79c)
2y ago
TCRR
TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
PremiumThe FlyTCR2 Therapeutics downgraded to Hold from Buy at Jefferies
2y ago
ADAP
TCRR
TCR2 Therapeutics downgraded to Hold from Buy at Truist
Premium
The Fly
TCR2 Therapeutics downgraded to Hold from Buy at Truist
2y ago
ADAP
TCRR
TCR2 Therapeutics downgraded to Hold from Buy at Truist
Premium
The Fly
TCR2 Therapeutics downgraded to Hold from Buy at Truist
2y ago
TCRR
TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
2y ago
ADAP
TCRR
Adaptimmune downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
Adaptimmune downgraded to Hold from Buy at JonesResearch
2y ago
ADAP
TCRR
Adaptimmune Craters after Acquiring TCRR
PremiumMarket News
Adaptimmune Craters after Acquiring TCRR
2y ago
ADAP
TCRR
Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction
PremiumThe Fly
Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction
2y ago
ADAP
TCRR
TCR2 Therapeutics price target raised to $10 from $8 at Piper Sandler
PremiumThe FlyTCR2 Therapeutics price target raised to $10 from $8 at Piper Sandler
2y ago
TCRR
TCR2 Therapeutics announces pipeline priorities for 2023
Premium
The Fly
TCR2 Therapeutics announces pipeline priorities for 2023
2y ago
TCRR
TCR2 Therapeutics initiated with a Hold at EF Hutton
Premium
The Fly
TCR2 Therapeutics initiated with a Hold at EF Hutton
2y ago
TCRR
TCR2 Therapeutics price target lowered to $8 from $16 at Piper Sandler
PremiumThe Fly
TCR2 Therapeutics price target lowered to $8 from $16 at Piper Sandler
2y ago
TCRR
TCR2 Therapeutics presents preclinical data on Gavo-cel
PremiumThe Fly
TCR2 Therapeutics presents preclinical data on Gavo-cel
2y ago
TCRR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >